首页> 美国卫生研究院文献>BMC Family Practice >Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) – study protocol for a pragmatic randomized controlled trial
【2h】

Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) – study protocol for a pragmatic randomized controlled trial

机译:药物不良反应高风险患者的个体化与标准化风险评估(IDrug)–实用的随机对照试验研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundElderly patients are particularly vulnerable to adverse drug reactions, especially if they are affected by additional risk factors such as multimorbidity, polypharmacy, impaired renal function and intake of drugs with high risk potential. Apart from these clinical parameters, drug safety and efficacy can be influenced by pharmacogenetic factors. Evidence-based recommendations concerning drug-gene-combinations have been issued by international consortia and in drug labels. However, clinical benefit of providing information on individual patient factors in a comprehensive risk assessment aiming to reduce the occurrence and severity of adverse drug reactions is not evident. Purpose of this randomized controlled trial is to compare the effect of a concise individual risk information leaflet with standard information on risk factors for side effects.
机译:背景老年患者特别容易受到药物不良反应的影响,特别是如果他们受到其他风险因素的影响,例如多发病,多药房,肾功能受损和高风险药物的摄入。除这些临床参数外,药物安全性和功效可能会受到药物遗传因素的影响。国际财团和药物标签已经发布了有关药物基因组合的循证建议。但是,在旨在降低药物不良反应的发生和严重程度的综合风险评估中提供有关个别患者因素的信息的临床益处尚不明显。这项随机对照试验的目的是比较简明的个人风险信息单张与有关副作用风险因素的标准信息的效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号